Experience
Biogen Int’l GmbH
Amneal Pharmaceuticals LLC
Represented Biogen in an ANDA litigation against 27 generic drug manufacturers in multiple jurisdictions concerning Biogen’s Tecfidera® (dimethyl fumarate) product for the treatment of relapsing forms of multiple sclerosis.
Biogen Int’l GmbH v. Amneal Pharmaceuticals LLC, 1:17-cv-00823, D. Del., Judges Stark, Noreika
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
Novartis Pharmaceuticals Corporation et al.
Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.
Biogen International GmbH
Grünenthal GmbH et al. v. Alvogen Pine Brook, Inc. et al.
Grünenthal GmbH et al.
Mylan Pharmaceuticals Inc. et al. v. Biogen MA Inc. et al.
Biogen MA Inc. et al.
AstraZeneca LP v. SigmaPharm Laboratories
AstraZeneca LP
BioDelivery Sciences International, Inc. et al. v. Alvogen PB Research & Development LLC et al.
BioDelivery Sciences International, Inc. et al.
Grünenthal GmbH et al. v. Actavis Elizabeth LLC et al.
Grünenthal GmbH
Alexander Sr. v. BMW of North America LLC, et al.
BMW of North America LLC, et al.
Real Time Social Inventions LLC v. Conduit USA, Inc. et al.
Conduit USA, Inc. et al.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.